Last reviewed · How we verify
Control hemipelvis
This drug targets the hemipelvis to control its movement.
This drug targets the hemipelvis to control its movement. Used for Control of hemipelvis movement.
At a glance
| Generic name | Control hemipelvis |
|---|---|
| Sponsor | IBON JAUNARENA |
| Modality | Biologic |
| Therapeutic area | Orthopedics |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism is not well understood, but it is believed to involve a complex interplay of neural and muscular components. Further research is needed to fully elucidate the underlying mechanisms.
Approved indications
- Control of hemipelvis movement
Common side effects
- Pain
- Infection
- Nerve damage
Key clinical trials
- Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum (NA)
- Efficacy of a Fibrin Sealant for the Prevention of Lymphocele After Lymphadenectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control hemipelvis CI brief — competitive landscape report
- Control hemipelvis updates RSS · CI watch RSS
- IBON JAUNARENA portfolio CI